Eledon Pharmaceuticals, Inc.
Funding history
About Eledon Pharmaceuticals, Inc.
How much funding has Eledon Pharmaceuticals, Inc. raised?
Eledon Pharmaceuticals, Inc. has raised $50.0M in total funding. The most recent round was Series E.
Where is Eledon Pharmaceuticals, Inc. headquartered?
Eledon Pharmaceuticals, Inc. is headquartered in Irvine, CA.
What problem does Eledon Pharmaceuticals, Inc. solve?
Organ transplant recipients face rejection of their transplanted organs, and there has been little innovation in immunomodulatory therapy since tacrolimus was approved 30 years ago.
What's Eledon Pharmaceuticals, Inc.'s solution?
Eledon is developing tegoprubart, an anti-CD40L antibody, and testing it in clinical trials (including the completed BESTOW Phase 2 trial and an ongoing Phase 1b trial) to prevent kidney and other organ transplant rejection.
What makes Eledon Pharmaceuticals, Inc. different?
The company targets the CD40 Ligand pathway, which its CEO states may more effectively control immune response and increase transplant durability compared to current treatment options.
What makes Eledon Pharmaceuticals, Inc. notable?
Eledon Pharmaceuticals was co-founded and is led by CEO David-Alexandre Gros, a physician and serial biotech entrepreneur, with investors including BVF Partners, RA Capital Management, and Blue Owl Capital.
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.